XHKG1672
Market cap495mUSD
Jan 07, Last price
3.35HKD
1D
-2.62%
1Q
151.88%
IPO
-71.75%
Name
Ascletis Pharma Inc
Chart & Performance
P/E
—
P/S
64.12
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.33%
Rev. gr., 5y
-19.39%
Revenues
57m
+4.63%
Net income
-145m
L-60.54%
CFO
-144m
L+1.20%
Earnings
May 22, 2025
Profile
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB) and human immunodeficiency virus functional cure; ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne, Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 56,596 4.63% | 54,090 -29.64% | ||||||
Cost of revenue | 310,350 | 378,298 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (253,754) | (324,208) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | 51,869 | |||||||
Tax Rate | ||||||||
NOPAT | (253,754) | (376,077) | ||||||
Net income | (144,715) -60.54% | (366,712) 81.42% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | (78,961) | 961 | ||||||
BB yield | 5.04% | -0.02% | ||||||
| Debt | ||||||||
Debt current | 5,710 | 2,416 | ||||||
Long-term debt | 11,122 | 6,058 | ||||||
Deferred revenue | 5,558 | 7,146 | ||||||
Other long-term liabilities | 7,146 | |||||||
Net debt | (380,152) | (2,484,378) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (144,162) | (142,453) | ||||||
CAPEX | (6,213) | (14,401) | ||||||
Cash from investing activities | 149,845 | (1,297,387) | ||||||
Cash from financing activities | (81,496) | (1,419) | ||||||
FCF | (248,990) | (327,138) | ||||||
| Balance | ||||||||
Cash | 2,303,246 | 2,482,034 | ||||||
Long term investments | (1,906,262) | 10,818 | ||||||
Excess cash | 394,154 | 2,490,148 | ||||||
Stockholders' equity | (449,116) | (326,945) | ||||||
Invested Capital | 2,805,156 | 2,883,807 | ||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 1,074,103 | 1,087,030 | ||||||
Price | 1.46 -69.20% | 4.74 44.07% | ||||||
Market cap | 1,568,191 -69.56% | 5,152,522 42.68% | ||||||
EV | 1,188,039 | 2,668,144 | ||||||
EBITDA | (235,274) | (294,017) | ||||||
EV/EBITDA | ||||||||
Interest | 144 | 157 | ||||||
Interest/NOPBT | ||||||||